LONDON, May 11 (Reuters) - AstraZeneca Plc hopes U.S. approval of a once-daily version of its blockbuster schizophrenia drug Seroquel, expected next week, can break a run of bad product news. The U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results